Intratumoral Synthesis of Two‐Photon NIR‐I Activated Photosensitizer Undergoing Oxygen‐Free Photo‐Redox Cycle for Hypoxic Tumor Phototherapy

Why It Matters

It delivers effective phototherapy without relying on tumor oxygen, addressing a major limitation of conventional PDT and expanding treatment options for hard‑to‑reach cancers.

Key Takeaways

• Intratumoral prodrug AICST activates via NIR‑I light
• Activation yields oxygen‑independent photosensitizer AICST‑SO3
• Photo‑redox cycle generates hydroxyl radicals without oxygen
• 800 nm irradiation ablates tumors in mouse models
• Strategy overcomes hypoxia limitation in photodynamic therapy

Pulse Analysis

Hypoxic tumor microenvironments have long crippled conventional photodynamic therapy (PDT), which depends on molecular oxygen to generate reactive species. By leveraging two‑photon NIR‑I excitation, the new AICST system penetrates deeper tissues while remaining inert until it encounters the targeted tumor site. The intratumoral synthesis model eliminates systemic exposure, ensuring that the photosensitizer is produced only where it is needed, thereby reducing off‑target effects and improving therapeutic index.

The chemistry behind AICST is a D‑π‑A architecture featuring a coumarin donor, a C═C π‑bridge, and an indole acceptor. Elevated intracellular sulfite (SO₃²⁻) triggers a rapid conversion to AICST‑SO3, which, upon NIR illumination, undergoes charge separation. The oxidized moiety extracts electrons from water, forming highly reactive hydroxyl radicals (·OH), while the reduced anionic radicals transfer electrons to pyruvic acid, sustaining an oxygen‑free photo‑redox cycle. This dual‑pathway mechanism ensures continuous cytotoxic activity even in severely oxygen‑deprived regions.

Preclinical validation demonstrated that a single 800 nm irradiation session virtually eradicated tumors in mouse models, highlighting the system’s potency and precision. The ability to activate therapy deep within tissue without oxygen opens avenues for treating pancreatic, brain, and other solid tumors where hypoxia is prevalent. As the field moves toward personalized, minimally invasive oncology, AICST‑based intratumoral synthesis could become a cornerstone technology, prompting further clinical trials and potential integration with imaging‑guided delivery platforms.